In this conversation From the Vault, panelists discuss implications of the semaglutide cirrhosis late-breaker and share what they anticipate might be different one year from the time of recording from ILC 2022.
Stephen Harrison and Jörn Schattenberg join Roger Green to digest and discuss key takeaways from the recently concluded EASL Congress 2023 and ADA 83rd Scientific Sessions. This final conversation considers important topics yet to be addressed in the preceding sessions. One of the prevailing themes explored is the potential of NASH drugs as adjuvant therapy.
Stephen Harrison and Jörn Schattenberg join Roger Green to digest and discuss key takeaways from the recently concluded EASL Congress 2023 and ADA 83rd Scientific Sessions. In this conversation, the group moves on from analysis around resmetirom to discuss other drug classes in the therapeutic landscape.
Stephen Harrison and Jörn Schattenberg join Roger Green to digest and discuss key takeaways from the recently concluded EASL Congress 2023 and ADA 83rd Scientific Sessions. In this conversation, the group continues to unpack fresh data on resmetirom, discuss its safety profile and speculate ideas around how the field could benefit from an improved understanding of liver volume dynamics.
Stephen Harrison and Jörn Schattenberg join Roger Green to digest and discuss key takeaways from the recently concluded EASL Congress 2023 and ADA Scientific Sessions. In this conversation, Stephen expounds on newly released Phase 3 MAESTRO-NASH data on resmetirom with powerful notes around endpoints, the study population and other elements critical to the full trial package.
Ken Cusi and Roger Green are joined by family practice researcher and KOL Eric Johnson and diabetologist and primary care KOL Jay Shubrook in a discussion around exciting news emerging from the ADA 83rd Scientific Sessions meeting. Layering in practical takeaways, the group explores their impressions from the meeting, the utility of FIB-4 as a frontline screening tool, guidelines and recommendations, therapeutic options both now and in the imminent future, and lastly the new nomenclature rollout for Fatty Liver disease.
Stephen Harrison and Jörn Schattenberg join Roger Green to discuss newly released Phase 3 MAESTRO-NASH data on resmetirom and the wider NASH therapeutic landscape, AI-assisted digital pathology, what the field understands about liver volume reduction, an increasing burden of cirrhosis and much more. This episode is packed with robust analysis and insights stemming from a busy past month at the EASL Congress and ADA Scientific Sessions meetings.
Roger Green is joined by Jörn Schattenberg to discuss a complex and developing NASH therapeutic landscape and takeaways from an exciting month of meetings. This final conversation explores a range of topics including the role of artificial intelligence and general observations around how the different questions being asked in 2023 versus 2019 demonstrate dramatic changes in how the field understands Fatty Liver disease.
Roger Green is joined by co-host Jörn Schattenberg to discuss a complex and developing NASH therapeutic landscape and takeaways from an exciting month of meetings. This conversation also features comments around the subject of new NAFLD/NASH nomenclature.
Roger Green is joined by KOL Mazen Noureddin to discuss a complex and developing NASH therapeutic landscape and takeaways from an exciting month of meetings. This final interview with Mazen is to be followed by a series of deep-dive episodes dedicated to unpacking the 2023 EASL Congress and the 83rd annual American Diabetes Association Scientific Sessions. Stay safe and surf on!
